

Clinical and molecular characterization of *KCNT1*-related severe early-onset epilepsy

Amy McTague, MBChB,* Umesh Nair, BScHons,* Sony Malhotra, PhD, Esther Meyer, PhD, Natalie Trump, PhD, Elena V. Gazina, PhD, Apostolos Papatheou, MBBS, Adeline Ngoh, MBBS, Sally Ackermann, MBChB, Gautam Ambegaonkar, MBBS, MRCPCH, Richard Appleton, MA(oxon), Archana Desurkar, MBBS, Christin Eltze, MBBS, MPhil, Rachel Kneen, BMedSci, BMBS, FRCPCH, Ajith V. Kumar, MD, MRCP, Karine Lascelles, MBBS, MRCPCH, Tara Montgomery, BMBS, BMedSci, FRCP, Venkateswaran Ramesh, MBBS, Rajib Samanta, MBBS, FRCPCH, Richard H. Scott, PhD, Jeen Tan, MBChB, MRCPCH, William Whitehouse, MBBS, MRCP, Annapurna Poduri, MD, MPH, Ingrid E. Scheffer, MBBS, PhD, W.K. "Kling" Chong, FRCR, J. Helen Cross, MBChB, PhD, Maya Topf, PhD, Steven Petrou, PhD and Manju A. Kurian, MRCPCH, PhD

Correspondence

Dr. McTague
a.mctague@ucl.ac.uk
or Dr. Kurian
manju.kurian@ucl.ac.uk

Neurology® 2018;90:e55-66. doi:10.1212/WNL.0000000000004762

Abstract

Objective

To characterize the phenotypic spectrum, molecular genetic findings, and functional consequences of pathogenic variants in early-onset *KCNT1* epilepsy.

Methods

We identified a cohort of 31 patients with epilepsy of infancy with migrating focal seizures (EIMFS) and screened for variants in *KCNT1* using direct Sanger sequencing, a multiple-gene next-generation sequencing panel, and whole-exome sequencing. Additional patients with non-EIMFS early-onset epilepsy in whom we identified *KCNT1* variants on local diagnostic multiple gene panel testing were also included. When possible, we performed homology modeling to predict the putative effects of variants on protein structure and function. We undertook electrophysiologic assessment of mutant *KCNT1* channels in a *xenopus* oocyte model system.

Results

We identified pathogenic variants in *KCNT1* in 12 patients, 4 of which are novel. Most variants occurred de novo. Ten patients had a clinical diagnosis of EIMFS, and the other 2 presented with early-onset severe nocturnal frontal lobe seizures. Three patients had a trial of quinidine with good clinical response in 1 patient. Computational modeling analysis implicates abnormal pore function (F346L) and impaired tetramer formation (F502V) as putative disease mechanisms. All evaluated *KCNT1* variants resulted in marked gain of function with significantly increased channel amplitude and variable blockade by quinidine.

Conclusions

Gain-of-function *KCNT1* pathogenic variants cause a spectrum of severe focal epilepsies with onset in early infancy. Currently, genotype-phenotype correlations are unclear, although clinical

*These authors contributed equally to this work.

From Molecular Neurosciences (A.M., E.M., A., A.N., M.A.K.), Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health; Department of Neurology (A.M., A., A.N., C.E., J.H.C., M.A.K.) and Neuroradiology (W.K.C.), Great Ormond Street Hospital for Children, London, UK; Florey Institute of Neuroscience and Mental Health (U.N., E.V.G., I.E.S., S.P.), Melbourne, Australia; Department of Biological Sciences (S.M., M.T.), Institute of Structural and Molecular Biology, Birkbeck College, University of London; Regional Molecular Genetics Laboratory (N.T., R.H.S.), North East Thames Regional Genetics Service, and Department of Clinical Genetics (A.V.K., R.H.S.), Great Ormond Street Hospital, London, UK; Department of Paediatric Neurology (S.A.), Red Cross War Memorial Children's Hospital, Cape Town, South Africa; Department of Paediatric Neurology (G.A.), Addenbrooke's Hospital, Cambridge; Roald Dahl EEG Unit (R.A.), Department of Neurology, and Department of Neurology (R.K.), Alder Hey Children's Hospital, Liverpool; Department of Paediatric Neurology (A.D.), Sheffield Children's Hospital; Clinical Neurosciences (C.E., J.H.C.), Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London; Institute of Infection and Global Health (R.K.), University of Liverpool; Department of Paediatric Neurology (K.L.), Evelina Children's Hospital, Guys and St. Thomas' NHS Foundation Trust, London; Department of Clinical Genetics (T.M.), Northern Genetics Service; Department of Pediatric Neurology (V.R.), Great North Children's Hospital, Newcastle Upon Tyne; Department of Paediatric Neurology (R.S.), University Hospital Leicester Children's Hospital; Department of Paediatric Neurology (J.T.), Royal Manchester Children's Hospital; Department of Paediatric Neurology (W.W.), Nottingham University Hospitals NHS Trust, UK; Epilepsy Genetics Program (A. Poduri), Department of Neurology, Boston Children's Hospital; Department of Neurology (A. Poduri), Harvard Medical School, Boston, MA; University of Melbourne (I.E.S.), Austin Health and Royal Children's Hospital, Australia; and Department of Medicine (S.P.), Royal Melbourne Hospital, University of Melbourne, Australia. Dr. Malhotra is currently at the Department of Biochemistry, University of Cambridge, UK.

Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

The Article Processing Charge was funded by The Wellcome Trust, Medical Research Council.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

outcome is poor for the majority of cases. Further elucidation of disease mechanisms may facilitate the development of targeted treatments, much needed for this pharmacoresistant genetic epilepsy.

Glossary

ADNFLE = autosomal dominant nocturnal frontal lobe epilepsy; **EIMFS** = epilepsy of infancy with migrating focal seizures; **EOEE** = early-onset epileptic encephalopathy; **NFLE** = nocturnal frontal lobe epilepsy; **RCK** = regulator of potassium conductance; **SLACK** = sequence like a calcium-dependent potassium channel; **WT** = wild-type.

Autosomal dominant pathogenic variants in *KCNT1*, encoding the sodium-activated potassium channel, are identified in a wide spectrum of epileptic disorders with variable age at onset and cognitive outcome. These include severe early-onset epileptic encephalopathies such as Ohtahara and West syndromes^{1,2} and epilepsy of infancy with migrating focal seizures (EIMFS),^{3–14} as well as autosomal dominant and sporadic severe nocturnal frontal lobe epilepsies (ADNFLE and NFLE),^{10,15,16} but the genotype-phenotype relationship appears to be unclear. We undertook detailed clinical, molecular genetic, and functional characterization of a cohort of patients with *KCNT1*-related epilepsy.

Methods

Patient recruitment

We recruited patients with EIMFS (n = 31) to a research study investigating the genetic basis of early-onset epileptic encephalopathy (EOEE) between 2011 and 2016, following an earlier national surveillance study.⁴ Inclusion criteria were epilepsy with onset at <2 years and unknown etiology. Diagnostic criteria for EIMFS were as described in the previous study.⁴ Patients were recruited at Great Ormond Street Hospital, London, UK, and by referral from other centers in the United Kingdom and internationally. Two patients who had routine local diagnostic multiple gene panel testing revealing *KCNT1* variants were also included.

Standard protocol approvals, registrations, and patient consents

We obtained written informed consent from families in whom research genetic investigations were undertaken. The study was approved by the National Research Ethics Service (London-Bloomsbury, Research Ethics Committee reference 13/LO/0168, Integrated Research Application System project identifier 95005). We collected anonymized data from patients tested on the diagnostic next-generation sequencing panel (n = 3) as part of an approved case note review project (Great Ormond Street Hospital Research and Development Department, 16NM11).

Genetic testing

We used a variety of different methods (table e-1, <http://links.lww.com/WNL/A6>), including direct Sanger sequencing,

multiple gene panel testing with the TruSeq Custom Ampli-con panel and SureSelect panel, exome sequencing (e-Methods, <http://links.lww.com/WNL/A8>; tables e-1 and e-2, <http://links.lww.com/WNL/A6>), and diagnostic chromosomal microarray.

Homology modeling

HMMscan¹⁷ against Pfam (database of sequence-based domain families)¹⁸ identified 2 domains in the sequence of human *KCNT1* (isoform 1): ion channel (PF07885, at position 278–346) and calcium-activated BK potassium channel alpha-subunit family (PF03493, at position 495–598) (e-Methods).

Electrophysiologic assessment of mutant *KCNT1* in *xenopus* oocyte model

We introduced variants into a wild-type (WT) human *KCNT1* expression construct¹⁹ using QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA). cDNAs were transcribed in vitro (mMessage mMachine; Ambion, Austin, TX). Oocytes were prepared, and 2-electrode voltage clamp recording was performed after 14 to 24 hours of expression. We also recorded currents before and after the application of Quinidine (e-Methods).

Results

Clinical and molecular genetic features of *KCNT1* mutation-positive patients

Clinical presentation

We identified pathogenic variants in *KCNT1* in 12 patients, 5 through direct Sanger sequencing, 2 from whole-exome sequencing, and 5 from the Great Ormond Street Hospital diagnostic panel (5 of 800 tested patients with EOEE/developmental delay).

Clinical features are summarized in table 1. Median age at seizure onset was 3.5 weeks (range 1 day–6 months). Most patients developed seizures consistent with EIMFS. Two patients (patients 3 and 11) presented with severe, early-onset NFLE, characterized by asymmetric tonic posturing and later fencing posture. We noted similar frontal seizure semiology in patients with EIMFS (e.g., patient 12). All patients developed axial hypotonia, and upper motor neuron signs emerged in 3

Table 1 Clinical and genetic features for 12 patients with *KCNT1* mutations

Patient	CDS/protein change	Inheritance	Dx methods	ECS	Age at onset	Initial seizure type	Subsequent seizure types	Autonomic features	MD (age at onset)	Additional features	Best developmental stage attained	Best response to treatment	Previous functional validation?
1 ^a	c.811G>T, V271F	Unknown (parental DNA not available)	WES, SS	EIMFS	2 wk	HV, eye jerking, oral automatisms, FM upper limbs	Asymmetric tonic posturing, My, GTCS	Facial flushing	—	—	No developmental milestones achieved	None	Gain of function ^{4,28}
2	c.820C>A, L274I	De novo	SS, NGSP	EIMFS	1 d	HV, ED and jerking, TS upper limbs	FM seizures of face and arm	—	—	—	No developmental milestones achieved	None (including quinidine)	No
3	c.862G>A, G288S	De novo	NGSP	NFLE	6 mo	Predominantly nocturnal, asymmetric tonic posturing	ED, choking noises, fencing posture, brief generalized TS and GTCS	Facial flushing	—	Right-sided neglect, increased tone on right side, peripheral hyperreflexia in lower limbs	Grasps objects and standing briefly at 2.5 y, vocalizing and babbling	None resulted in seizure freedom	Gain of function ^{5,8–10,13,26,28,33}
4	c.1038C>G, F346L	De novo	SS	EIMFS	7 wk	Exaggerated startle, reflex warm water clonic/My, evolved to HV and ED, tonic posturing upper limbs, FM all limbs	Rapid alternating ED, facial grimacing leading to airway obstruction	Drooling, salivation, apneas	HK MD affecting upper limbs (18 mo)	Coarse facial features, gum hypertrophy	Normal development until 10 wk, then regression with loss of social smile and head control	None	No
5	c.1504T>G, F502V	Maternal inheritance, likely somatic mosaicism	SS	EIMFS	3 mo	Behavioural arrest, staring, upward eye rolling, HV and ED to either side, asymmetric tonic posturing and elevation of limbs	Flexor spasms involving the trunk, clonic seizures of limbs, eyelid twitching, gelastic seizures	—	HK MD disorder involving head and all limbs (18 mo)	Cleft of hard palate	Early social smile and visual interaction, lost after onset of epilepsy	KD with vigabatrin, effect later lost Quinidine-marked reduction in seizures	No
6	c.2687T>A, M896K	De novo	NGSP	EIMFS	2 wk	Brief FM all limbs (twitching)	HV, dystonic posturing upper limbs, ED and jerking	Facial flushing, noisy breathing	HK movement perioral muscles, tongue, hand, and wrists (2 y)	Systemic proliferative vasculopathy of pulmonary and mediastinal vessels	No developmental milestones achieved	None (including quinidine)	No
7	c.2849G>A, R950Q	Paternally inherited	SS	EIMFS	5 mo	HV, TS	TS, gelastic seizures	—	HK MD (14 mo)	—	Normal until seizure onset, (smile and head control), regression at 5 mo with no further development	None	No ⁹

Continued

Table 1 Clinical and genetic features for 12 patients with *KCNT1* mutations (continued)

Patient	CDS/ protein change	Inheritance	Dx methods	ECS	Age at onset	Initial seizure type	Subsequent seizure types	Autonomic features	MD (age at onset)	Additional features	Best developmental stage attained	Best response to treatment	Previous functional validation?
8	c.2800G>A, A934T	De novo	SS	EIMFS	4 wk	HV, ED, fisting of hands	Asymmetric tonic posturing, ED, oral 9 automatisms	Facial flushing	Limb dystonia and severe scoliosis (18 mo)	Peripheral hypertonia	Babbling, some degree of head control	Steroids and KD in combination at 7–12 mo	Gain of function ^{3,4,8,9,20}
9 ^a	c.2800G>A, A934T	De novo	WES	EIMFS	2 wk	HV, ED, vocalization	T10S with adverse component	Facial flushing, pupillary dilation	—	Gastrointestinal dysmotility	Partial head control, smiling	Nitrazepam at 5 mo	
10	c.2800G>A, A934T	De novo	NGSP	EIMFS	3 wk	HV, ED with pupil jerking, FM arm and face, oral automatisms	HV, ED, drooling, TS with adverse component, FM upper limbs	Facial flushing	—	—	Smiling, visual awareness, some head control, rolling	Stiripentol, levetiracetam, and clonazepam in combination	
11	c.2800G>A, A934T	De novo	NGSP	NFLE	8 wk	Focal motor seizures hands, ED and jerking, TS upper limb and FM contralateral lower limb Seizures only in sleep Stopped at 4–5 mo	From 11 mo: TS with fist clenching, ED, asymmetric tonic posturing, mainly from sleep	—	—	Right-sided weakness with peripheral hyperreflexia	Walking before regression at 11 mo, best subsequent stage sitting independently	No sustained response	
12	c.2800G>A, A934T	De novo	NGSP	EIMFS	3 wk	ED with eye flickering, HV, TS upper limbs	FM upper and lower limbs with lip smacking, hand fisting, HV and ED, fencing posture of arm	Facial flushing	—	—	Social smile and reaching for objects until regression and loss of these skills at 5 mo	KD and lacosamide in combination	

Abbreviations: CDS = coding sequence; Dx = diagnostic; ECS = electroclinical syndrome; ED = eye deviation; EIMFS = epilepsy of infancy with migrating focal seizures; FM = focal motor; GTCS = generalized tonic-clonic seizures; HK = hyperkinetic; HV = head version; KD = ketogenic diet; MD = movement disorder; My = myoclonic seizures; NFLE = nocturnal frontal lobe epilepsy; NGSP = next-generation sequencing panel; SS = Sanger sequencing; TS = tonic seizures.

^a Previously described by McTague et al.⁴

patients. Four patients had a choreiform movement disorder (onset 14–24 months); 1 patient developed generalized dystonia at 18 months. Onset of hyperkinesia was not related to medication (including vigabatrin) nor triggered by intercurrent illness. Initial age at presentation, disease course, response to medication, brain MRI, and EEG findings were similar for both *KCNT1* pathogenic variant–positive and –negative patients from the cohort. However, 5 of 12 pathogenic variant–positive patients with EIFMS presented with a severe movement disorder compared to 2 of 19 *KCNT1*-negative cases. Most had extensive uninformative laboratory metabolic and genetic investigations. Abnormal muscle respiratory chain enzyme activity for complex I and/or II was detected in patients 4 and 8 of uncertain significance (table e-3, <http://links.lww.com/WNL/A6>). For patient 4, the muscle biopsy was taken during an intercurrent illness and repeated after clinical recovery, revealing a more borderline result. In patient 8, borderline abnormalities in complex I and II ratios were found. Neither patient had other systemic, biochemical, or radiologic features of mitochondrial disease or concurrent sodium valproate treatment.

In general, neurodevelopmental outcome was markedly impaired in all patients with EIFMS. All patients had a trial of at least 5 different medications. Response to treatment was, in general, poor (table 1). Three of 8 patients who received the ketogenic diet in combination with other antiepileptic drugs responded with $\approx 75\%$ seizure reduction. Three patients were treated with quinidine. Patient 2 received 40 mg/kg/d without adverse events but with no effect on seizure burden. Patient 5 was treated with quinidine at 40 mg/kg/d, leading to a marked reduction in seizure frequency. Patient 6 showed some initial transient reduction in seizure frequency at 30 mg/kg/d. For this patient, the unexpected development of a severe proliferative pulmonary and mediastinal vasculopathy resulted in life-threatening pulmonary hemorrhage. Investigations failed to identify an underlying vasculitis, and quinidine was subsequently withdrawn. The patient later died despite initial successful pulmonary embolization.

EEG features

All patients with an EIFMS phenotype had a “migrating” ictal focus with discrete ictal involvement of differing cortical areas within the same EEG (table e-4, <http://links.lww.com/WNL/A6>). Although not always evident at initial presentation, it developed by 7 months of age in most patients. Periods of EEG suppression or burst suppression were noted in 8 of 12 patients; 6 of these patients had seizure onset in the first 4 weeks of life. Further atypical EEG features included a generalized electrodecremental response in 5 patients and hypsarhythmia in 1 patient.

Radiologic features

Neuroimaging was available for review in 11 of 12 patients. The majority developed predominantly frontal cerebral atrophy by 3 years of age (figures e-1A and e-1B, <http://links.lww.com/>

[WNL/A6](http://links.lww.com/WNL/A6); table e-5, <http://links.lww.com/WNL/A6>). Cerebellar atrophy was also evident in 4 patients (figure e-1C). We noted an open operculum in the first 6 months of life in patient 4 (figure e-1B). Delayed myelination was evident in 9 of 11 patients who had imaging after 3 months of age. In some patients, early brain imaging was normal. Magnetic resonance spectroscopy was abnormal with a relatively reduced N-acetylcholine peak in 3 of 4 patients.

Molecular genetic findings


We identified 12 patients with pathogenic variants in *KCNT1* (table 1 and table e-6, <http://links.lww.com/WNL/A6>); 8 have been previously reported and 4 are unpublished.^{4,5,9,10,16} Eight of 12 patients had C-terminus variants, of whom 5 had the commonly reported variant A934T. We have identified 4 (including 2 unpublished) pathogenic variants causing EIFMS, namely V271F, L274I, G288S, and F346L located in or between transmembranes 5 and 6. All are missense variants that are predicted to be pathogenic (table e-6), affecting highly conserved amino acid residues (figure e-2, <http://links.lww.com/WNL/A7>), and are not reported in 1000 Genomes, the ExAC database, or the Exome Variant Server.^{20–24} For 9 of 12 cases, variants occurred de novo. Parental DNA was not available for patient 1. In patient 5, we found the same *KCNT1* variant in an asymptomatic mother and her affected child. We noted a lower heterozygous peak on Sanger sequencing of both salivary and blood-derived maternal genomic DNA (figure e-3), which may reflect somatic mosaicism. In patient 7, the variant was inherited from the unaffected father with no difference in peak size on Sanger sequencing (figure e-4). The recurrent A934T variant was identified in 5 patients, 4 with an EIFMS presentation and 1 (patient 11) with an NFLE phenotype.

Protein homology modeling of mutant *KCNT1*

Homology modeling was performed for 2 novel mutations: F346L, located in the ion channel domain (residues 270–353), and F502V, located in the gating region (residues 373–1174, although residues 1,045–1,174 could not be modeled). F346 is located on the inner helix of the transmembrane pore (figure 1, A and B). It is part of the hydrophobic cavity, which mediates interactions between the inner-membrane helices of 2 adjacent subunits (figure 1C) and is thus responsible for maintaining the stability of the open conformation. In the modeled closed-state conformation, the helix containing F346 and the inner helix from the other protomer undergo conformational changes (figure e-5, <http://links.lww.com/WNL/A7>). Therefore, mutation to leucine (F346L) is likely to destabilize the open state by perturbing the hydrophobic interactions because the side chain of leucine is smaller (figure 1D), affecting the equilibrium between the closed and open states. In addition, the packing arrangement in the K⁺ channels involving the pore and the inner helix is known to be critical for the stability of the tetrameric assembly, ion conduction function, and cation selectivity. Thus, F346L might be detrimental to these functions.²⁵

Within each protomer of the *KCNT1* gating region, there are 2 tandem RCK domains (RCK1 and RCK2) that serve as

Figure 1 Modeling the ion channel and gating apparatus of *KCNT1*



(A) Side view of the homology model of the *KCNT1* ion channel (residues 278–346) as a tetramer. F346 is present on the edge of the inner helix (in gold) and interacts with the inner helix of the adjacent subunit in the tetrameric arrangement. Membrane position is shown in spheres. (B) Top view of the tetramer arrangement of the ion channel and location of F346 on the inner helix. (C) F346 is part of the hydrophobic cavity (shown as surface), which mediates interactions between the inner membrane helices of the 2 subunits. F346 is shown in green; the surrounding hydrophobic residues are shown in red. (D) On mutation to leucine (F346L, in green), the hydrophobic interactions between the 2 subunits are likely to be reduced (black circle) because the side chain of leucine is much shorter than phenylalanine. (E) Model of a dimer of the gating ring (residues 373–1,044; residues 1,045–1,174 could not be modeled), which is a tetramer (dimer of the modeled dimer). Each subunit possesses 2 RCK domains: RCK1 (in blue) and RCK2 (in gold). F502 (in green) is present in the RCK1 domain, near the intersubunit interface (assembly interface). The RCK1-RCK2 intrasubunit interface is purple (residues from RCK1) and orange (residues from RCK2). The dimer interfaces formed by both RCK-1 and RCK-2 are indicated by an arrow. (F) F502 (green) and its neighboring hydrophobic residues (red), including W476, with which it could potentially form a pi-pi interaction. Distance between the centroid (spheres) of the 2 rings (F502 and W476) is 4.7 Å, and the angle between the ring planes is 27.3°. (G) F502V could abolish the formation of the potential pi-pi interaction with W476 and is likely to reduce the hydrophobic interactions (black circle) because the side chain of valine is smaller than that of phenylalanine.

regulators of potassium conductance (figure 1E). These form flexible intrasubunit and intersubunit (figure 1E) interfaces that facilitate functional tetramer formation.²⁶ F502 is located in RCK1 and predicted to form a pi-pi interaction with W476 from α D (figure 1F). F502 is also surrounded by a number of hydrophobic residues (I472, L473, A475, V500, and A503), which may play a role in stabilizing the gating ring (figure 1F). The amino acid substitution F502V is predicted to result in destabilization of these hydrophobic interactions, given the smaller valine side chain (figure 1G), and abolition of potential pi-stacking with resultant disruption of the stable assembly interface.

Electrophysiologic assessment of mutant KCNT1

We evaluated the 4 previously unpublished variants and V271F, which we previously described⁴ and was recently studied in a *xenopus* oocyte system.²⁷ All mutations resulted in an increased current magnitude compared to WT (figure 2A). We noted that for variants V271F and F346L, the rate of activation was slowed at higher voltages compared to WT, and in others (M896K, F502V and L274I), the activation rates were generally faster than WT (figure 2A). Investigation of the current-voltage relationship showed that mutant channels were very weakly voltage dependent, and in some cases, voltage dependence of steady-state activation was essentially absent (figure 2, B and C) with only a residual Goldman-Hodgkin-Katz rectification. Assessment of average peak currents at 10 mV revealed a significant difference between both individual mutant channels and summated data compared to WT (figure 2, D and E).

Effect of 300 μ mol/L quinidine on mutant KCNT1

Quinidine 300 μ mol/L had variable current-blocking effects in different mutant channels. For F346L, peak current was completely insensitive to quinidine, although it had some effect on activation kinetics (figure 3A). The differential sensitivity of KCNT1 mutants to quinidine was clearly shown in the current-voltage relationship (figure 3B) and percentage of inhibition at maximum current, 80 mV (figure 3C). There is some correlation between the in vitro studies and clinical response in patient 5 (figure 3). M896K had the most marked in vitro blockade by quinidine, and patient 6 showed some initial clinical response. F346L showed no quinidine response at all, and the patient harboring this mutation was not treated with quinidine.

Discussion

We report a cohort of patients with early-onset epilepsy associated with pathogenic variants in *KCNT1*, which encodes the sodium-activated potassium channel KCa4.1 (sequence like a calcium-dependent potassium channel [SLACK], Slo2.2). *KCNT1* is widely expressed throughout the brain, as well as in the dorsal root ganglia, kidney, and heart, and is responsible for slow hyperpolarization after bursts of action


potentials.^{28,29} *KCNT1* also has direct interactions with Fragile X-related protein.²⁹ Compared with other potassium channels, *KCNT1* is involved in a highly extensive protein network, suggesting a putative role in cognitive developmental processes.^{3,8,28,30}

To date, *KCNT1* variants have been reported in a wide range of epilepsies (table e-7, <http://links.lww.com/WNL/A6>).^{1-16,31,32} We identified patients with the same variant associated with varying electroclinical phenotypes (table 1). Phenotypic variability has been reported within single families in which different individuals may present with either ADNFLE or EIMFS.¹⁰ Such intrafamilial variation in phenotype is also described in *SCN1A* kindreds; Dravet syndrome, febrile seizures, and a variety of other generalized epilepsies may be reported in the same family.³³ Furthermore, while the majority of variants in our cohort occurred de novo, 2 patients inherited variants from an unaffected parent. The mechanisms underlying phenotypic variability and true/apparent nonpenetrance are unclear but may be related to somatic mosaicism, variant type, other genetic/epigenetic factors, or differential expression of alternative *KCNT1* transcripts.^{9,10,29,34,35}

The majority of patients with pathogenic *KCNT1* variants in our cohort had electroclinical EIFMS, although this is likely to reflect ascertainment bias. Indeed, 2 of the 5 *KCNT1*-positive patients identified by the diagnostic panel from a larger cohort of 800 patients with EOEE/developmental delay had an NFLE-like presentation. Although movement disorders are increasingly reported in other severe early-onset genetic epilepsies, they appear to be rare in *KCNT1* epilepsy.³⁶ We describe several atypical EEG features. Generalized electrodecrement and hypsarrhythmia, more classically associated with infantile spasms, have been previously described in EIMFS.^{2,4,9,10,31} EEG suppression, classically seen in Ohtahara syndrome,³⁷ has been only rarely described in EIMFS.^{4,9} Extensive diagnostic investigations undertaken in patients with *KCNT1* mutations were unyielding other than abnormal respiratory chain enzyme analysis of muscle tissue in 2 patients. The relevance of these findings is not clear, but secondary mitochondrial effects may be evident in *KCNT1* epilepsy, as often reported in other severe drug-resistant epilepsies.³⁸ Other genetic and environmental influences on mitochondrial function may also play a role.

KCNT1 tetramers form a transmembrane sodium-activated potassium channel. Each subunit consists of 6 transmembrane domains with an extended cytoplasmic carboxy (C-) terminus (figure 4). The majority of reported pathogenic variants (table e-7, <http://links.lww.com/WNL/A6>), as seen in this study, are located in the C-terminus with clustering around the RCK and nicotinamide adenine dinucleotide-binding domains (figure 4). More recently, several variants have been identified within transmembrane domain 5 and in the pore-forming regions between transmembrane domains 4 and 5^{4,5,8-10} (table e-7), and this study also demonstrates epilepsy-associated mutations in transmembrane domains.

Figure 2 Functional investigation of *KCNT1* mutations in a *xenopus* oocyte model




(A) Representative current traces obtained from oocytes expressing WT and EIMFS mutants (M896K, F502V, V271F, F346L, and L274I). Oocytes were held at -90 mV and stepped from -80 to 80 mV for 600 milliseconds every 5 seconds. Scale bars apply to all traces. (B) Current-voltage relationships for WT ($n = 32$), M896K ($n = 15$), F502V ($n = 13$), V271F ($n = 9$), F346L ($n = 11$), and L274I ($n = 12$). Currents were averaged and then normalized to the value at a test potential of 80 mV (I_{max}). (C) Comparison of current-voltage relationships between WT (solid circles, $n = 32$) and EIMFS mutations (M896K [squares, $n = 15$], F502V [triangles, $n = 13$], V271F [hexagons, $n = 9$], F346L [diamonds, $n = 11$], and L274I [inverted triangles, $n = 12$]). Currents were averaged and then normalized to the value at a test potential of 80 mV (I_{max}). (D) Average peak currents at 10 mV for WT ($n = 44$), M896K ($n = 19$), F502V ($n = 16$), V271F ($n = 10$), F346L ($n = 11$), and L274I ($n = 12$) channels. Peak currents for each mutant channel at 10 mV were compared to the peak currents for the WT channel at 10 mV. *** $p < 0.001$, **** $p < 0.0001$. (E) Comparison of pooled WT ($n = 44$) and EIMFS ($n = 68$) currents at 10 mV. **** $p < 0.0001$. EIMFS = epilepsy of infancy with migrating focal seizures; WT = wild-type.

To date, different model systems have been used to determine the functional effects of *KCNT1* variants.^{1,5,7,10,13,19,27} Our protein homology structural modeling data predict abnormal gating or protein instability within the pore-forming region as a putative disease mechanism. In silico modeling of G288S has predicted similar detrimental effects,⁵ while Y775H is predicted to affect sodium sensitivity of the channel.²⁷ *KCNT1* variants may therefore alter structural properties of the protein, contributing to altered channel function. Consistent with previous reports^{1,3,13,19,27} (table e-7, <http://links.lww.com/WNL/A6>), our *xenopus* oocyte model demonstrated that *KCNT1* pathogenic variants display a gain-of-function effect with increased current amplitude (figure 2). Previous studies have sought to correlate disease severity with the degree of gain of

function.^{1,19} However, in keeping with more recent studies,⁸ such correlation was not evident in our study. *KCNT1* variants result in an increased P_o (probability of the channel being open), which may be due to increased mutant channel cooperativity or altered sodium sensitivity.^{8,27} In a recent study, sodium removal from the pipette solution had a less negative effect on G288S channel amplitude than WT, suggesting reduced sodium sensitivity in the mutant.¹³ Heterotetramer formation may be of importance in vivo. In 1 study, mutant *KCNT1* homomers revealed a more marked gain of function than mutant WT heteromers.¹³ A significant remaining question is how *KCNT1* gain-of-function variants with predicted effects on neuronal hyperpolarization result in epilepsy.²⁸ Altered voltage sensitivity may result in *KCNT1* channels

Figure 3 Effect of quinidine on *xenopus* oocytes expressing h*KCNT1* channels




(A) Representative current traces obtained from oocytes expressing WT and EIMFS mutants (M896K and F346L) with application of vehicle (ND96) and 300 μmol/L quinidine. Oocytes were held at -90 mV and stepped from -80 to 80 mV for 600 milliseconds every 5 seconds. Scale bars apply to all traces. (B) Current-voltage relationships for WT (n = 32), M896K (n = 15), F502V (n = 13), V271F (n = 9), F346L (n = 11), and L274I (n = 12) h*KCNT1* channels in the presence of vehicle (ND96) and 300 μmol/L quinidine. Currents were averaged and then normalized to the value at a test potential of 80 mV (I_{max}). (C) Average percent inhibition at 80 mV of WT (n = 31) and EIMFS (M896K, n = 15; F502V, n = 13; V271F, n = 9; F346L, n = 11; and; L274I, n = 12) h*KCNT1* channels by quinidine (300 μmol/L) depicting the variable degree of block by 300 μmol/L quinidine (1-way analysis of variance followed by Bonferroni post hoc analysis). * $p < 0.1$. EIMFS = epilepsy of infancy with migrating focal seizures; WT = wild-type.

opening at more depolarized potentials, allowing a persistent hyperpolarizing current, with resultant interneuronal disinhibition as reported in *SCN1A*-related epilepsy.³⁹ Conversely, increased repolarization permitting more frequent and rapid action potentials may also play a role.^{27,34}

Recently, quinidine has been identified as a novel therapy for patients with *KCNT1*-related epilepsy. In in vitro models, quinidine has been shown to reduce the abnormal increase in mutant *KCNT1* channel amplitude.¹⁹ For 1 patient with EIMFS with the *KCNT1* variant R428Q, in vitro testing showed quinidine sensitivity, and treatment resulted in a dramatic improvement in seizure control with neurodevelopmental gains.^{3,7} However, in more recent studies, patient response has been variable and not always as predicted by in vitro studies.¹¹ Indeed, another patient

with the same variant (R428Q) but different epilepsy phenotype (unclassified EOEE) failed to respond to quinidine, albeit at a later stage in the disease course.¹⁴ Most recently, a patient with West syndrome had a good response but only with a higher dose of 60 mg/kg/d.² Clinical response may possibly be determined by the specific variant, other genetic factors, epilepsy phenotype, and drug timing within a therapeutic window. In our series, we treated 3 patients with quinidine, and 1 patient showed a clinical response. One patient developed a severe pulmonary vasculopathy, after which quinidine was discontinued. Systemic vasculitis has been reported with quinidine treatment.⁴⁰ While investigations in our patient did not reveal overt evidence of vasculitis, the observed pulmonary dysfunction may represent an adverse drug-related event. The precise mechanism of *KCNT1* blockade by quinidine is unclear, and it is possible that the disease mechanism for

Figure 4 Schematic diagram of the location of mutations in *KCNT1* in this and previously published studies



KCNT1 encodes sequence like a calcium-dependent potassium channel (SLACK), which forms tetramers (top left) or heteromers with *KCNT2* or sequence like an intermediate conductance K channel (SLICK). The structure comprises 6 transmembrane domains with a pore-forming region, regulator of potassium conductance (RCK), and nicotinamide adenine dinucleotide-binding (NAD-B) domains. EIMFS phenotypes are shaded in purple, ADNFLE or NFLE in pink, others (Ohtahara syndrome, leukoencephalopathy, focal epilepsy, EOEE, West syndrome, unaffected) in orange. Mutations giving rise to >1 phenotype are shaded with a combination of the corresponding colors. Novel mutations identified in this study are outlined in green, those identified in previous studies in turquoise. ADNFLE = autosomal dominant nocturnal frontal lobe epilepsy; EIMFS = epilepsy of infancy with migrating focal seizures; EOEE = early-onset epileptic encephalopathy; NFLE = nocturnal frontal lobe epilepsy.

F346L, perhaps involving abnormal channel-opening dynamics as suggested by the modeling data, is not modifiable by quinidine. Our data suggest that quinidine should be considered as a therapeutic option for patients with *KCNT1* variants, but used with caution. Larger studies will provide further guidance about clinical utility, patient selection, optimum age at administration, and dose. Other *KCNT1* modulators, including bepridil and clofilium, have been identified as possible alternative therapies.²⁸ Like quinidine, bepridil has been shown in vitro to reversibly block mutant *KCNT1* channels at a lower concentration than WT channels.¹³ However, similar to quinidine, potential cardiac effects and lack of specificity may limit use in patients.

Pathogenic variants in *KCNT1* cause a wide spectrum of severe epilepsies typically associated with impaired neurologic

development and significant disease burden. As demonstrated, in vitro model systems may be useful to validate putative variants and to confirm pathogenicity, although genotype-phenotype correlations remain unclear. Evaluation of new therapies, including *KCNT1*-specific blockers, remains a research priority for this devastating pharmacoresistant group of epilepsies.

Note added in proof

Recently, 3 patients with de novo *KCNT1* mutations and massive systemic to pulmonary collateral artery formation, presenting with pulmonary hemorrhage requiring embolization, were described. These patients had not been treated with quinidine. However, the mechanism remains unclear and further investigation of the expression and role of *KCNT1* in the cardiovascular system is required.⁴¹

Author contributions

Amy McTague, Umesh Nair, Sony Malhotra, and Esther Meyer have contributed to drafting/ revising the manuscript for content, including medical writing for content, study concept or design, acquisition of data, analysis or interpretation of data. Natalie Trump has contributed to drafting/ revising the manuscript for content, including medical writing for content, acquisition of data, analysis or interpretation of data. Elena V. Gazina, Apostolos Papandreou, and Adeline Ngoh have contributed to drafting/ revising the manuscript for content, acquisition of data, analysis or interpretation of data. Sally Ackermann and Gautam Ambe-gaonkar have contributed to drafting/ revising the manuscript for content, acquisition of data. Richard Appleton has contributed to drafting/ revising the manuscript for content, including medical writing for content, acquisition of data, analysis or interpretation of data. Archana Desurkar has contributed to drafting/ revising the manuscript for content, acquisition of data. Christin Eltze and Rachel Kneen have contributed to drafting/ revising the manu-script for content, including medical writing for content, acqui-sition of data, analysis or interpretation of data. Ajith V. Kumar and Karine Lascelles have contributed to drafting/ revising the manuscript for content, acquisition of data. Tara Montgomery has contributed to drafting/ revising the manuscript for content, acquisition of data, analysis or interpretation of data. Ven-kateswaran Ramesh and Rajib Samanta have contributed to drafting/ revising the manuscript for content, acquisition of data. Richard H. Scott has contributed to drafting/ revising the man- uscript for content, acquisition of data, analysis or interpretation of data. Jeen Tan has contributed to drafting/ revising the manu- script for content, acquisition of data. William Whitehouse and Annapurna Poduri have contributed to drafting/ revising the manuscript for content, including medical writing for content, acquisition of data. Ingrid E. Scheffer, W.K. “Kling” Chong, and J. Helen Cross have contributed to drafting/ revising the manu- script for content, including medical writing for content, acqui- sition of data, analysis or interpretation of data. Maya Topf, Steven Petrou, and Manju A. Kurian have contributed to drafting/ revising the manuscript for content, including medical writing for content, study concept or design, acquisition of data, analysis or interpretation of data.

Acknowledgment

The authors thank the patients and their families for their participation in this study. They thank all clinicians referring patients with EIMFS for inclusion in the research study (Dr. Mike Pike, Dr. Stefan Spinty, Dr. Ailsa McLellan, Dr. Mary King, Dr. Andrew Curran, Dr. Hans Randby, Dr. Linda de Meirleir, Dr. Jost Richter, Dr. Elaine King, Dr. Martin Piepkorn, Dr. Mary O’Regan, Dr. Ariane Biebl, Dr. Gary McCullagh, and Dr. Siobhan West). They thank Erin Heinzen, PharmD, PhD, for whole-exome sequencing of 5 patients at the Duke Center for Genomic Medicine, Durham, NC.

Study funding

This project was supported by the National Institute for Health Research Biomedical Research Centre at Great

Ormond Street Hospital for Children NHS Foundation Trust and University College London.

Disclosure

A. McTague was funded by a Medical Research Council Clinical Research Training Fellowship (MR/L001497/1), the Medical Research Foundation for travel and conference fees (MRF-007-0003-STD-MCTAG), a Grass Foundation Travel Bursary from the American Epilepsy Society, and a Junior Investigator travel scholarship from the University of South California. U. Nair and S. Malhotra report no disclosures relevant to the manuscript. E. Meyer is funded by SPARKS. N. Trump reports no disclosures relevant to the manuscript. E.V. Gazina is funded by the Australian Research Council (APP1106027). A. Papandreou is funded by a joint Action Medical Research and British Paediatric Neurology Association research training fellowship. A. Ngoh is funded by Guarantors of Brain, Friends of Landau Kleffner Syndrome and Action Medical Research. S. Ackermann and G. Ambe-gaonkar report no disclosures relevant to the manuscript. R. Appleton served on the scientific committees for and received a single honorarium from Novartis and GW Pharma and is the Chief Investigator for the EcLiPSE Study funded by an National Institute for Health Research Health Technology As- sessment grant (12/127/134). A. Desurkar, C. Eltze, R. Kneen, A.V. Kumar, K. Lascelles, T. Montgomery, V. Ramesh, R. Samanta, and R.H. Scott report no disclosures relevant to the manuscript. J. Tan received an industry-funded bursary for conference travel (£300) from UCB Pharma. W. Whitehouse serves on the editorial board of NeuroEducation. A. Poduri is on the Scientific Advisory Board of the Dravet Syndrome Foundation, serves as an associate editor for *Epilepsia* and contributing editor for *Epilepsy Currents*, and is on the editorial board for *Annals of Neurology*. She receives research support from the National Institute of Neurological Disorders and Stroke (NINDS), Citizens United for Research in Epilepsy, and the Boston Children’s Hospital Translational Research Program. I.E. Scheffer serves on the editorial boards of *Neu- rology* and *Epileptic Disorders*; may accrue future revenue on a pending patent WO61/010176: Therapeutic Compound that relates to discovery of PCDH19 gene; is one of the inventors listed on a patent held by Bionomics Inc on di- agnostic testing of using the *SCN1A* gene, WO2006/133508; has received speaker honoraria or scientific board consulting fees from Athena Diagnostics, UCB, GSK, Eisai, and Trans- genomics; has received funding for travel from Athena Diag- nostics, UCB, Eisai, and GSK; and has received research support from the National Health and Medical Research Council of Australia, NINDS, Health Research Council of New Zealand, US Department of Defense, and March of Dimes. W.K. Chong reports no disclosures relevant to the manuscript. J.H. Cross is on the advisory boards of Shire, GSK, Eisai, Vitaflo, UCB, and Takeda for which remuneration has been made to her department; has a patent in application with Vitaflo; and is the chief investigator for clinical trials with Vitaflo, GW Pharma, and Zogenix for which remuneration has been made to the department. M. Topf reports no disclosures

relevant to the manuscript. S. Petrou is scientific founder of Praxis Precision Medicine, Boston, and a Scientific Advisory Board Member of Pairnomix, Minneapolis, and has received shares for both. Dr. Petrou's research is supported by the Lulu Foundation, Vitaflo/Nestle, Citizens United for Research in Epilepsy, Mallinckrodt Pharmaceuticals, Clarus Ventures, DHB Foundation, Australian Research Council, National Health and Medical Research Council, and SCN2A Research Foundation. M.A. Kurian receives research/grant support from a Wellcome Trust Intermediate Clinical Fellowship (WT098524MA). Go to Neurology.org/N for full disclosures.

Received November 7, 2016. Accepted in final form September 26, 2017.

References

- Martin HC, Kim GE, Pagnamenta AT, et al. Clinical whole-genome sequencing in severe early-onset epilepsy reveals new genes and improves molecular diagnosis. *Hum Mol Genet* 2014;23:3200–3211.
- Fukuoka M, Kuki I, Kawawaki H, et al. Quinidine therapy for West syndrome with KCNT1 mutation: a case report. *Brain Dev* 2017;39:80–83.
- Barcia G, Fleming MR, Deligniere A, et al. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. *Nat Genet* 2012;44:1255–1259.
- McTague A, Appleton R, Avula S, et al. Migrating partial seizures of infancy: expansion of the electroclinical, radiological and pathological disease spectrum. *Brain* 2013;136:1578–1591.
- Ishii A, Shioda M, Okumura A, et al. A recurrent KCNT1 mutation in two sporadic cases with malignant migrating partial seizures in infancy. *Gene* 2013;531:467–471.
- Vanderver A, Simons C, Schmidt JL, et al. Identification of a novel de novo p. Phe932Ile KCNT1 mutation in a patient with leukoencephalopathy and severe epilepsy. *Pediatr Neurol* 2014;50:112–114.
- Bearden D, Strong A, Ehnott J, DiGiovine M, Dlugos D, Goldberg EM. Targeted treatment of migrating partial seizures of infancy with quinidine. *Ann Neurol* 2014;76:457–461.
- Kim GE, Kronengold J, Barcia G, et al. Human slack potassium channel mutations increase positive cooperativity between individual channels. *Cell Rep* 2014;9:1661–1672.
- Ohba C, Kato M, Takahashi N, et al. De novo KCNT1 mutations in early-onset epileptic encephalopathy. *Epilepsia* 2015;56:e121–e128.
- Møller RS, Heron SE, Larsen LHG, et al. Mutations in KCNT1 cause a spectrum of focal epilepsies. *Epilepsia* 2015;56:e114–e120.
- Mikati MA, Jiang Y-H, Carboni M, et al. Quinidine in the treatment of KCNT1 positive epilepsies. *Ann Neurol* 2015;78:995–999.
- Allen NM, Conroy J, Shahwan A, et al. Unexplained early onset epileptic encephalopathy: exome screening and phenotype expansion. *Epilepsia* 2015;57:e12–e17.
- Rizzo F, Ambrosino P, Guacci A, et al. Characterization of two de novo KCNT1 mutations in children with malignant migrating partial seizures in infancy. *Mol Cell Neurosci* 2016;72:54–63.
- Chong PF, Nakamura R, Saitsu H, Matsumoto N, Kira R. Ineffective quinidine therapy in early-onset epileptic encephalopathy with KCNT1 mutation. *Ann Neurol* 2016;79:502–503.
- Heron SE, Smith KR, Bahlo M, et al. Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy. *Nat Genet* 2012;44:1188–1190.
- Hildebrand MS, Myers CT, Carvill GL, et al. A targeted resequencing gene panel for focal epilepsy. *Neurology* 2016;86:1605–1612.
- Eddy SR. Accelerated profile HMM searches. *PLoS Comput Biol* 2011;7:e1002195.
- Finn RD, Mistry J, Tate J, et al. The Pfam protein families database. *Nucleic Acids Res* 2009;38:D221–D222.
- Milligan CJ, Li M, Gazina EV, et al. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine. *Ann Neurol* 2014;75:581–590.
- 1000 Genomes. Available at: <http://browser.1000genomes.org/index.html>. Accessed June 14, 2016.
- ExAC Browser (beta)|Exome Aggregation Consortium. Available at: <http://exac.broadinstitute.org/>. Accessed June 14, 2016.
- NHLBI Exome Sequencing Project (ESP). Available at: <http://evs.gs.washington.edu/EVS/>. Accessed June 14, 2016.
- PolyPhen-2. Available at: <http://genetics.bwh.harvard.edu/pph2/>. Accessed June 14, 2016.
- Available at: http://provean.jcvi.org/genome_submit_2.php. Accessed June 14, 2016.
- Doyle DA, Morais Cabral J, Pfuetzner RA, et al. The structure of the potassium channel: molecular basis of K⁺ conduction and selectivity. *Science* 1998;280:69–77.
- Yuan P, Leonetti MD, Pico AR, Hsiung Y, MacKinnon R. Structure of the human BK channel Ca²⁺-activation apparatus at 3.0 Å resolution. *Science* 2010;329:182–186.
- Tang Q-Y, Zhang F-F, Xu J, et al. Epilepsy-related slack channel mutants lead to channel over-activity by two different mechanisms. *Cell Rep* 2016;14:129–139.
- Kaczmarek LK. Slack, slick, and sodium-activated potassium channels. *ISRN Neurosci* 2013;2013:354262.
- Brown MR, Kronengold J, Gazula V-R, et al. Amino-termini isoforms of the slack K⁺ channel, regulated by alternative promoters, differentially modulate rhythmic firing and adaptation. *J Physiol* 2008;586:5161–5179.
- Kim GE, Kaczmarek LK. Emerging role of the KCNT1 slack channel in intellectual disability. *Front Cell Neurosci* 2014;8:209.
- Allen AS, Berkovic SF, Cossette P, et al. De novo mutations in epileptic encephalopathies. *Nature* 2013;501, 217–221.
- Arai-Ichinoi N, Uematsu M, Sato R, et al. Genetic heterogeneity in 26 infants with a hypomyelinating leukodystrophy. *Hum Genet* 2015;135:89–98.
- Scheffer IE, Zhang Y-HH, Jansen FE, Dibbens L. Dravet syndrome or genetic (generalized) epilepsy with febrile seizures plus? *Brain Dev* 2009;31:394–400.
- Lim CX, Ricos MG, Dibbens LM, Heron SE. KCNT1 mutations in seizure disorders: the phenotypic spectrum and functional effects. *J Med Genet* 2016;53:217–225.
- Chen H, Kronengold J, Yan Y, et al. The N-terminal domain of slack determines the formation and trafficking of slick/slack heteromeric sodium-activated potassium channels. *J Neurosci* 2009;29:5654–5665.
- Howell KB, McMahon JM, Carvill GL, et al. SCN2A encephalopathy: a major cause of epilepsy of infancy with migrating focal seizures. *Neurology* 2015;85:958–966.
- Ohtahara S. A study on the age dependent epileptic encephalopathy. *No To Hattatsu* 1977;9:2–21.
- Folbergrová J, Kunz WS. Mitochondrial dysfunction in epilepsy. *Mitochondrion* 2012;12:35–40.
- Yu FH, Mantegazza M, Westenbroek RE, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. *Nat Neurosci* 2006;9:1142–1149.
- Lipsker D, Walther S, Schulz R, Navé S, Cribier B. Life-threatening vasculitis related to quinidine occurring in a healthy volunteer during a clinical trial. *Eur J Clin Pharmacol* 1998;54:815.
- Kawasaki Y, Kuki I, Ehara E, et al. Three cases of KCNT1 mutations: malignant migrating partial seizures in infancy with massive systemic to pulmonary collateral arteries. *J Pediatr Epub* 2017 October 5.

Clinical and molecular characterization of *KCNT1*-related severe early-onset epilepsy

Amy McTague, MBChB, Umesh Nair, BSc Hons, Sony Malhotra, PhD, Esther Meyer, PhD, Natalie Trump, PhD, Elena V. Gazina, PhD, Apostolos Papandreou, MBBS, Adeline Ngoh, MBBS, Sally Ackermann, MBChB, Gautam Ambegaonkar, MBBS, MRCPCH, Richard Appleton, MA(Oxon), Archana Desurkar, MBBS, Christin Eltze, MBBS, MPhil, Rachel Kneen, BMedSci, BMBS, FRCPCH, Ajith V. Kumar, MD, MRCP, Karine Lascelles, MBBS, MRCPCH, Tara Montgomery, BM, BS, BMedSci, FRCP, Venkateswaran Ramesh, MBBS, Rajib Samanta, MBBS, FRCPCH, Richard H. Scott, PhD, Jeen Tan, MBChB, MRCPCH, William Whitehouse, MBBS, MRCP, Annapurna Poduri, MD, MPH, Ingrid E. Scheffer, MBBS, PhD, W. K. "Kling" Chong, FRCP, J. Helen Cross, MBChB, PhD, Maya Topf, PhD, Steven Petrou, PhD, and Manju A. Kurian, MRCPCH, PhD

Correspondence

Dr. McTague
a.mctague@ucl.ac.uk or
Dr. Kurian
manju.kurian@ucl.ac.uk

Neurology® 2018;90:24. doi:10.1212/WNL.0000000000004762

Study question

What are the phenotypic, molecular genetic, and functional characteristics of *KCNT1* variants that cause early-onset epilepsy?

Summary answer

Gain-of-function *KCNT1* mutations can cause diverse severe focal epilepsies with onset in early infancy, but genotype-phenotype relationships remain unclear.

What is known and what this paper adds

Autosomal dominant pathogenic variants of the sodium-activated potassium channel gene *KCNT1* are associated with a broad spectrum of epileptic disorders. The study explores the clinical, molecular genetic, and functional properties of a cohort of patients with *KCNT1*-related epilepsy.

Participants and setting


Thirty-one patients with epilepsy of infancy with migrating focal seizures (EIMFS) were recruited from 2011 to 2016. Two patients who had undergone routine genetic testing that included *KCNT1* analysis were also included. The patients were recruited at London's Great Ormond Street Hospital and by referrals from UK and international centers.

Design, size, and duration

The patients' *KCNT1* variants were identified via multiple methods, and homology modeling was performed. The mutant *KCNT1* variants were electrophysiologically assessed in a *Xenopus* oocyte model.

Main results and the role of chance

Pathogenic *KCNT1* mutations were detected in 12 patients. These patients exhibited diverse symptoms. The ages at onset ranged from 1 day to 6 months, and all had neurodevelopmental impairments. Treatment outcomes were generally poor. The pathogenic *KCNT1* variants included 8 previously reported and 4 unreported variants. Homology modeling for 2 unreported variants indicated that they would induce abnormal gating or protein instability. Electrophysiologic assessments of 5



variants, including the 4 unreported ones, revealed abnormal channel functions, including increased current magnitudes relative to the wild-type (WT) channel and variable blockade by quinidine, in keeping with the clinical response.

Bias, confounding, and other reasons for caution

Focusing on patients with EIMFS may have introduced ascertainment bias.

Generalizability to other populations

Pathogenic *KCNT1* mutations have been detected in patients with epileptic conditions other than EIMFS, including nocturnal frontal lobe epilepsy. Such mutations may have different effects in other conditions.

Study funding/potential competing interests

This study was funded by the UK National Health Service and University College London. Some authors report receiving funding, personal compensation, and advisory committee appointments from various companies, journals, scholarly societies, and government agencies. Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures.

A draft of the short-form article was written by M. Dalefield, a writer with Editage, a division of Cactus Communications. The authors of the full-length article and the journal editors edited and approved the final version.

Neurology[®]

Clinical and molecular characterization of *KCNT1*-related severe early-onset epilepsy

Amy McTague, Umesh Nair, Sony Malhotra, et al.

Neurology 2018;90:e55-e66 Published Online before print December 1, 2017

DOI 10.1212/WNL.0000000000004762

This information is current as of December 1, 2017

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/90/1/e55.full
References	This article cites 35 articles, 6 of which you can access for free at: http://n.neurology.org/content/90/1/e55.full#ref-list-1
Citations	This article has been cited by 4 HighWire-hosted articles: http://n.neurology.org/content/90/1/e55.full##otherarticles
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): Ion channel gene defects http://n.neurology.org/cgi/collection/ion_channel_gene_defects Neonatal seizures http://n.neurology.org/cgi/collection/neonatal_seizures
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

